Ferring
Also known as: FerrÃng Pharmaceuticals | FERRING | Ferring Arzneimittel GmbH | Ferring Holding Ltd. | Ferring Pharmaceuticals | Ferring Pharmaceuticals A/S | Ferring Pharmaceuticals Inc. | Ferring Pharmaceuticals Korea, Ltd. | FERRING PHARMS INC | Ferring SAU
Highest phase reached
Phase 4
First clinical trial
May 1, 1996First marketed drug
Mar 5, 1973First NDA
Mar 5, 1973Last known activity
Sep 1, 2025
Timeline
1950s
- Jul 1, 1950
Ferring— Founded
2000s
- Jan 12, 2004
Dupomar SA— Acquired
2010s
- Oct 20, 2011
Cytokine PharmaSciences— Acquired
- Feb 18, 2015
Biosurface Engineering Technologies, Inc— Acquired
- Dec 8, 2017
ganciclovir— Marketing Organization
- Apr 5, 2018
Rebiotix Inc.— Acquired
2020s
- Dec 16, 2022
nadofaragene firadenovec— NDA Organization
- Dec 16, 2022
nadofaragene firadenovec— NDA Secondary Org
Drugs by trial phase (96 distinct, 239 trials)
Phase 4 (24 own, 0 via acquisition)
Phase 3 (32 own, 1 via acquisition)
Phase 2 (18 own, 10 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Adenomyosis
- Amenorrhea
- Anovulation
- Aortic Valve Stenosis
- Cardiovascular Diseases
- Colitis
- Colitis, Ulcerative
- Constipation
- Constriction, Pathologic
- Crohn Disease
- Diabetes Insipidus
- Diabetes Insipidus, Neurogenic
- Diarrhea
- Dwarfism, Pituitary
- Endocrine System Diseases
- Endometrial Hyperplasia
- Endometrial Neoplasms
- Endometriosis
- Enuresis
- Esophagitis
- Esophagitis, Peptic
- Gonadal Dysgenesis
- Hemorrhage
- Hepatorenal Syndrome
- Hyperphagia
- Hyperplasia
- Hypersensitivity
- Hypertension
- Hypertension, Portal
- Hypogonadism
- Hyponatremia
- Infertility
- Infertility, Female
- Lower Urinary Tract Symptoms
- Menorrhagia
- Nocturia
- Nocturnal Enuresis
- Obstetric Labor, Premature
- Osteoarthritis
- Osteoarthritis, Knee
- Ovarian Hyperstimulation Syndrome
- Polycystic Ovary Syndrome
- Polyuria
- Postpartum Hemorrhage
- Prader-Willi Syndrome
- Premature Birth
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Shock
- Shock, Septic
- Syndrome
- Turner Syndrome
- Ulcer
- Urinary Bladder, Overactive
- Urinary Incontinence
- von Willebrand Diseases
Marketed drugs (22)
Subsidiaries (4 direct, 9 total across the full acquisition tree)
Recent trials (50)
- NCT07153367CollaboratorPhase 2Sep 1, 2025
- NCT06668493OfficialPhase 1/Phase 2Nov 30, 2024
- NCT06668493Lead sponsorPhase 1/Phase 2Nov 30, 2024
- NCT06545955OfficialPhase 2Oct 1, 2024
- NCT06510374Lead sponsorPhase 3Oct 1, 2024
- NCT06545955Lead sponsorPhase 2Oct 1, 2024
- NCT06511791OfficialPhase 1Jul 15, 2024
- NCT06511791Lead sponsorPhase 1Jul 15, 2024
- NCT06515834OfficialPhase 1Jul 1, 2024
- NCT06515834Lead sponsorPhase 1Jul 1, 2024
- NCT06390111OfficialPhase 4Jun 17, 2024
- NCT06390111Lead sponsorPhase 4Jun 17, 2024
- NCT06466486OfficialPhase 1Jun 14, 2024
- NCT06466486Lead sponsorPhase 1Jun 14, 2024
- NCT06173869Lead sponsorPhase 3Apr 1, 2024
Details
- Founded
- Saint-prex, CH Jul 1, 1950
- First NDA
- Mar 5, 1973
- Last known activity
- Sep 1, 2025
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy
Notes
Acquired Rebiotix 5 Apr 2018 Acquire BioSET 19 Feb 2015